BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.6%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$10.2B
AUM Growth
+$10.2B
(+8.4%)
Cap. Flow
+$197M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
30.33%
Holding
228
New
12
Increased
78
Reduced
41
Closed
15
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$72M |
| 2 |
Tandem Diabetes Care
TNDM
|
$48M |
| 3 |
IQVIA
IQV
|
$42.6M |
| 4 |
Adaptive Biotechnologies
ADPT
|
$39.3M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$39M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$238M |
| 2 |
Moderna
MRNA
|
$62.9M |
| 3 |
Cigna
CI
|
$45.4M |
| 4 |
Bristol-Myers Squibb
BMY
|
$41.5M |
| 5 |
DaVita
DVA
|
$39.6M |
Sector Composition
| 1 | Healthcare | 96.41% |
| 2 | Industrials | 0.94% |
| 3 | Technology | 0.31% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Glaukos
GKOS
$5.42B
| $42M | 0.41% |
495,432
+6,090
| +1% | +$517K |
|
77
Health Catalyst
HCAT
$228M
| $41.8M | 0.41% |
753,621
+11,766
| +2% | +$653K |
|
78
Teleflex
TFX
$5.57B
| $40.2M | 0.39% |
100,161
-21,200
| -17% | -$8.52M |
|
79
Mersana Therapeutics
MRSN
$34.8M
| $39.9M | 0.39% |
117,640
+3,640
| +3% | +$1.24M |
|
|
80
Adaptive Biotechnologies
ADPT
$1.96B
| $39.3M | 0.38% |
+962,352
| New | +$39.3M |
|
81
Option Care Health
OPCH
$4.7B
| $39.2M | 0.38% |
1,790,192
+281,872
| +19% | +$6.16M |
|
|
HZNP
82
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $39.1M | 0.38% |
417,700
+9,200
| +2% | +$861K |
|
83
Phreesia
PHR
$1.81B
| $38.2M | 0.37% |
622,542
+9,529
| +2% | +$584K |
|
84
Quanterix
QTRX
$202M
| $37.4M | 0.37% |
637,815
-59,617
| -9% | -$3.5M |
|
85
NeoGenomics
NEO
$1.06B
| $37M | 0.36% |
818,313
+30,360
| +4% | +$1.37M |
|
86
AbbVie
ABBV
$374B
| $36.5M | 0.36% |
324,200
-59,900
| -16% | -$6.75M |
|
87
Illumina
ILMN
$15.2B
| $35.6M | 0.35% |
77,439
+14,815
| +24% | +$6.82M |
|
88
Exact Sciences
EXAS
$9.33B
| $34.3M | 0.33% |
275,673
+57,533
| +26% | +$7.15M |
|
89
HUTCHMED
HCM
$2.62B
| $34M | 0.33% |
864,760
-110,728
| -11% | -$4.35M |
|
90
Amgen
AMGN
$153B
| $31.6M | 0.31% |
129,580
-46,860
| -27% | -$11.4M |
|
91
Masimo
MASI
$7.43B
| $31M | 0.3% |
127,713
+1,517
| +1% | +$368K |
|
|
NVRO
92
DELISTED
NEVRO CORP.
NVRO
| $30.4M | 0.3% |
183,201
+2,188
| +1% | +$363K |
|
93
AtriCure
ATRC
$1.73B
| $29.7M | 0.29% |
374,418
-123,294
| -25% | -$9.78M |
|
94
Cooper Companies
COO
$13.3B
| $29.4M | 0.29% |
297,064
+19,596
| +7% | +$1.94M |
|
|
ONC
95
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.5B
| $28.9M | 0.28% |
84,300
+24,600
| +41% | +$8.44M |
|
|
ONEM
96
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $27.6M | 0.27% |
836,190
+13,055
| +2% | +$432K |
|
97
American Well
AMWL
$112M
| $26.9M | 0.26% |
107,088
+13,666
| +15% | +$3.44M |
|
|
VCRA
98
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $26M | 0.25% |
652,832
+160,725
| +33% | +$6.4M |
|
99
NeueHealth
NEUE
$60.6M
| $25.7M | 0.25% |
+18,750
| New | +$25.7M |
|
100
Kezar Life Sciences
KZR
$28.5M
| $24.6M | 0.24% |
453,315
| – | – |
|